Skip to content
WyteRock E-Books

WyteRock Blog

FDA-cleared, now Europe: the five decisions that decide an EU MedTech launch

WyteRock Global · 2026-10-30

A 510(k) clearance is a useful asset in Europe but not a shortcut. Classification, notified body, clinical evidence, economic operators and national reimbursement each need a deliberate decision, made early.

A 510(k) clearance rests on substantial equivalence to a predicate device. The EU Medical Device Regulation, Regulation (EU) 2017/745 (MDR), asks a different question: does the manufacturer's own technical documentation, including clinical evidence, demonstrate conformity with the general safety and performance requirements in Annex I? Much of a US file carries over. Its underlying logic does not. Five decisions determine how long the European launch takes and what it costs.

1. Classification

The MDR has four classes (I, IIa, IIb, III), assigned by the 22 rules in Annex VIII, with no official crosswalk from FDA classes. Software shows the gap most clearly. Under Rule 11, software providing information used for diagnostic or therapeutic decisions is at least class IIa; class IIb if those decisions could cause serious deterioration of health or a surgical intervention; class III if they could cause death or irreversible deterioration. Class decides whether a notified body is involved (always, except for class I devices that are not sterile, measuring or reusable surgical instruments) and how much clinical evidence is expected. MDCG 2021-24 is the reference guidance. The Commission's December 2025 proposal, COM(2025) 1023, would rewrite Rule 11, but it is still before the Parliament and the Council; classify under the current text.

2. The notified body

The Commission-funded 20th notified body survey (data to 28 February 2026, published 2 July 2026) counts 52 bodies designated under the MDR. In 65% of cases, an application reaches a signed written agreement within two months; the review is the slow part. From written agreement to a new quality-system-plus-product certificate, 51% of notified bodies reported 13 to 18 months and 31% reported 19 to 24 months. Choose a body whose designation scope in NANDO covers your device codes, and plan accordingly. An ISO 13485 quality system helps, but it will be audited against MDR Article 10(9).

3. Clinical evidence

Article 61 and Annex XIV Part A require a clinical evaluation. Much of the 510(k) file supports it: bench, biocompatibility, electrical safety, software and usability data map onto the Annex II technical documentation, and sound clinical investigations of the device itself, including US studies, are clinical data under the MDR.

The predicate argument does not transfer. Equivalence under Annex XIV Section 3 requires technical, biological and clinical similarity and sufficient access to the other device's data (MDCG 2020-5). For implantable and class III devices, Article 61(4) requires clinical investigations save narrow exceptions, and equivalence to another manufacturer's device requires a contract granting full ongoing access to its technical documentation (Article 61(5)). A competitor's predicate rarely qualifies.

Obligations continue after certification. Post-market clinical follow-up (PMCF) under Annex XIV Part B needs a plan and evaluation reports (MDCG 2020-7 and 2020-8). For class III and implantable devices, these and the summary of safety and clinical performance are updated at least annually (Article 61(11)). Periodic safety update reports (Article 86) are due annually for classes IIb and III and at least every two years for class IIa.

4. Authorised representative and economic operators

A manufacturer outside the EU must designate a sole authorised representative (Article 11), who verifies the declaration of conformity and technical documentation, keeps copies, handles registration and cooperates with authorities. Where the manufacturer has not met its Article 10 obligations, the representative is jointly and severally liable for defective devices (Article 11(5)), so expect due diligence before signature. Manufacturer and representative each need a person responsible for regulatory compliance (Article 15). The importer must verify conformity and put its name on the device or packaging (Article 13); distributors have duties under Article 14. Manufacturers must hold product-liability coverage (Article 10(16)).

5. Market access and reimbursement

The CE mark grants market access; payment remains national. In France, the LPPR list reimburses devices used outside hospital. The HAS committee CNEDiMTS assesses expected benefit (service attendu) and improvement over a comparator (ASA, graded I to V), and the price is negotiated with the CEPS. The dossier is filed in French; hospital devices are mostly funded within GHS tariffs. In Germany, inpatient care is paid through G-DRG tariffs. A method those tariffs do not cover adequately can receive supplementary NUB funding, but only hospitals can request it, from InEK, by 31 October for the following year. Digital health applications use BfArM's DiGA Fast-Track (§ 139e SGB V), with provisional listing for up to 12 months while evidence matures; class IIb applications must show the care effect at first listing. Under Regulation (EU) 2021/2282, a few high-risk devices now undergo EU joint clinical assessment (about five in 2026), which informs national decisions without replacing them.

Two further points: language and EUDAMED

Article 10(11) lets each Member State set the language of labels and instructions. The Commission's language table (Rev. 3, August 2025) shows France requiring French, and Germany requiring German for lay users while accepting English for professional users only in justified cases (§ 8(2) MPDG). Following Commission Decision (EU) 2025/2371 (published 27 November 2025), four EUDAMED modules have been mandatory since 28 May 2026: actor registration, UDI and device registration, notified bodies and certificates, and market surveillance. A new device must be registered before it is placed on the market. The vigilance and clinical-investigation modules are not yet released; those reports still follow national routes.

Summary: the five decisions

  1. Classification: classify under MDR Annex VIII; expect software to move up a class.
  2. Notified body: select by designation scope; plan for 13 to 24 months from contract to certificate.
  3. Clinical evidence: reuse US test and study data; do not rely on predicate equivalence; budget for PMCF.
  4. Economic operators: appoint an authorised representative, PRRC and importer before launch.
  5. Reimbursement: plan each country separately (LPPR in France; G-DRG, NUB or DiGA in Germany).

Also: translate labels and IFUs for each Member State, and register the actor and device in EUDAMED before first placing on the market.

Alex Mansour is CEO of WyteRock Global, a France-based life-sciences advisory firm that supports manufacturers on EU market entry for medical devices.

Sources

  1. Regulation (EU) 2017/745 on medical devices (Articles 10, 11, 13, 14, 15, 61, 86; Annexes VIII, XIV). EUR-Lex: https://eur-lex.europa.eu/eli/reg/2017/745/oj/eng
  2. Article texts as reproduced at medical-device-regulation.eu: Article 11 https://www.medical-device-regulation.eu/mdr-article-11-authorised-representative/ ; Article 61 https://www.medical-device-regulation.eu/mdr-article-61-clinical-evaluation/ ; Article 15 https://www.medical-device-regulation.eu/mdr-article-15-person-responsible-for-regulatory-compliance/
  3. Austrian National Public Health Institute, Areté, Civic Consulting for the European Commission, Survey results of the 20th NB survey (MDR/IVDR), data status 28 February 2026 (2 July 2026). https://health.ec.europa.eu/document/download/59b9d90e-be42-4895-9f6f-bec35138bb0a_en?filename=md_nb_survey_certifications_applications_en.pdf
  4. European Commission, NANDO database of notified bodies. https://webgate.ec.europa.eu/single-market-compliance-space/notified-bodies
  5. MDCG 2021-24, Guidance on classification of medical devices; MDCG 2020-5, Clinical evaluation: equivalence; MDCG 2020-7 and 2020-8, PMCF plan and evaluation report templates. https://health.ec.europa.eu/medical-devices-sector/new-regulations/guidance-mdcg-endorsed-documents-and-other-guidance_en
  6. European Commission, COM(2025) 1023 final, 2025/0404(COD) (16 December 2025). https://health.ec.europa.eu/document/download/25e7ea7c-cab3-40cf-86d9-d11f5e7744d8_en?filename=md_com_2025-1023_act_en.pdf
  7. European Commission, MDR: Language requirements for manufacturers, Rev. 3 (August 2025). https://health.ec.europa.eu/document/download/aa9760e3-c864-4173-8b16-d790dac66d74_en?filename=md_sector_lang-req-table-mdr.pdf
  8. European Commission, EUDAMED overview (Decision (EU) 2025/2371; mandatory modules since 28 May 2026). https://health.ec.europa.eu/medical-devices-eudamed/overview_en
  9. Haute Autorité de Santé, Déposer un dossier d'évaluation d'un dispositif médical (LPPR guide, SESAME platform). https://www.has-sante.fr/jcms/c_464498/fr/modalites-pratiques-de-depot-d-un-dossier-aupres-de-la-cnedimts ; HAS, Principes d'évaluation de la CNEDiMTS (2025). https://www.has-sante.fr/upload/docs/application/pdf/2025-09/principes_devaluation_de_la_cnedimts_liste_des_produits_et_prestations_remboursables_lppr_ou_la_liste_positive_intra-ghs.pdf
  10. InEK, Anfragen nach § 6 Abs. 2 KHEntgG (NUB). https://www.g-drg.de/neue-untersuchungs-und-behandlungsmethoden-nub/drg/verfahrenseckpunkte/anfragen-nach-6-abs.-2-khentgg-neue-untersuchungs-und-behandlungsmethoden9
  11. BfArM, DiGA-Leitfaden: Das Fast-Track-Verfahren für digitale Gesundheitsanwendungen nach § 139e SGB V. https://www.bfarm.de/SharedDocs/Downloads/DE/Medizinprodukte/diga_leitfaden.pdf ; GKV-Spitzenverband, Fokus: DiGA. https://www.gkv-spitzenverband.de/gkv_spitzenverband/presse/fokus/fokus_diga.jsp
  12. HTA Coordination Group, Annual Work Programme 2026 (Regulation (EU) 2021/2282). https://health.ec.europa.eu/document/download/81db097f-a9cb-4404-837c-115b4289321d_en?filename=hta_hatcg_2026-awp_en.pdf

Get new articles by email. Sign up for the newsletter or join the CentiAgent Club; members receive an alert for every new article.